

CCR MANUSCRIPT NOTIFICATION (JULY 2011)

Laboratory of Immune Cell Biology - Jonathan Ashwell, M.D.

There were no submissions reported this month.

Vaccine Branch - Jay Berzofsky, M.D., Ph.D.

Vargas-Inchaustegui DA, Demberg T, and **Robert-Guroff M**: A CD8 α - subpopulation of macaque circulatory natural killer cells can mediate both antibody-dependent and independent cytotoxic activities. *Immunology*. In press. (VB)

CCR Nanobiology Program - Robert Blumenthal, Ph.D.

Bindewald E, Wendeler M, Legiewicz M, Bona MK, Wang Y, Pritt MJ, **Le Grice SFJ**, and **Shapiro BA**: Correlating SHAPE signatures with 3D RNA structures. *RNA*. In press. (CCRNP)

Gong R, Wang Y, Feng Y, Zhao Q, and **Dimitrov DS**: Shortened engineered human antibody CH2 domains: Increased stability and binding to the human neonatal receptor. *J. Biol. Chem.* In press. (CCRNP)

Xiao X, Feng Y, Zhu Z, and **Dimitrov DS**: Identification of a putative Crimean-congo hemorrhagic fever virus entry factor. *Biochem. Biophys. Res. Commun.* In press. (CCRNP)

Zhao Q, Feng Y, Zhu Z, and **Dimitrov DS**: Human monoclonal antibody fragments binding to insulin-like growth factors 1 and 2 with picomolar affinity. *Mol. Cancer Ther.* In press. (CCRNP)

Zhu Z, Qin HR, Chen W, Zhao Q, Shen X, Schutte R, Wang Y, Ofek G, Streaker E, Prabakaran P, Fouda GG, Liao HX, Owens J, Louder M, Yang Y, Klaric KA, Moody A, Mascola JR, Scott JK, Kwong PD, Montefiori D, Haynes BF, Tomaras GD, and **Dimitrov DS**: Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. *J. Virol.* In press. (CCRNP)

Laboratory of Population Genetics - Kenneth Buetow, Ph.D.

There were no submissions reported this month.

Molecular Discovery Program - R. Andrew Byrd, Ph.D.

Structural Biophysics Laboratory - R. Andrew Byrd, Ph.D.

There were no submissions reported this month.

Molecular Targets Laboratory - James McMahon, Ph.D.

There were no submissions reported this month.

Chemical Biology Laboratory - Joel Schneider, Ph.D.

Liu F, Park JE, Qian WJ, Graber M, Berg T, Yaffe MB, Lee KS, and **Burke Jr TR**: Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel. *Nat Chem Biol*. In press. (CBL)

Kim SE, Bahta M, Lountos GT, Ulrich RG, **Burke Jr TR**, and **Waugh DS**: Isothiazolidinone (IZD) as a phosphoryl mimetic in inhibitors of the *Yersinia pestis* protein tyrosine phosphatase YopH. *Acta Crystallographica*. D67: 639-346, 2011. (CBL)

Liao CZ, Sitzmann M, Pugliese A, and **Nicklaus MC**: Software and resources for computational medicinal chemistry. *Future Med Chem*. 3(8): 1057-1085, 2011. (CBL)

Giano MC, Pochan DJ, and **Schnieder JP**: Controlled biodegradation of self-assembling β -hairpin peptide hydrogels by proteolysis with matrix metalloproteinase-13. *Biomaterials*. 32: 6471-6477, 2011. (CBL)

Radiation Oncology Branch - Kevin Camphausen, M.D.

Nayak TK and **Brechbiel MW**: ⁸⁶Y Based PET Radiopharmaceuticals: Radiochemistry and Biological Applications. *Med Chem*. In press. (ROB)

Song HA, Kang CS, Baidoo KE, Milenic DE, Chen Y, Dai A, **Brechbiel MW**, and Chong HS: Efficient Bifunctional Decadentate Ligand 3p-C-DEPA for Targeted α -Radioimmunotherapy Applications. *Bioconjug Chem*. 22(6): 1128-1135, 2011. (ROB)

Wuthrick EJ, Kamrava M, Curran Jr WJ, Werner-Wasik M, **Camphausen KA**, Hyslop T, Axelrod R, Andrews DW, Glass J, Machtay M, and Dicker AP: A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies. *Cancer*. In press. (ROB)

Housri N, Ning H, Ondos J, **Choyke P**, **Camphausen K**, **Citrin D**, Arora B, Shankavaram U, and Kaushal A: Parameters favorable to intraprostatic radiation dose escalation in men with localized prostate cancer. *Int J Radiat Oncol Biol Phys*. 80(2): 614-620, 2011. (ROB)

Urick ME, Chung EJ, Shield III WP, Gerber N, White A, Sowers A, Thetford A, **Camphausen K**, **Mitchell J**, and **Citrin DE**: Enhancement of 5-Fluorouracil-induced In Vitro and In Vivo Radiosensitization with MEK Inhibition. *Clin Cancer Res*. In press. (ROB)

de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, Deangelis L, **Camphausen K**, Chen A, Yung W, Prados M, Wen PY, and Heymach JV: Myeloid Biomarkers Associated with Glioblastoma Response to Anti-VEGF Therapy with Aflibercept. *Clin Cancer Res.* 17(14): 4872-4881, 2011. (ROB)

Lonser RR, Song DK, Klapper J, Hagan M, Auh S, Kerr PB, **Citrin DE**, Heiss JD, **Camphausen K**, and **Rosenberg SA**: Surgical management of melanoma brain metastases in patients treated with immunotherapy. *J Neurosurg.* 115(1): 30-36, 2011. (ROB)

Smith B, Lyakhov I, Loomis K, Needle D, Baxa U, Yavlovich A, **Capala J**, **Blumenthal R**, and Puri A: Hyperthermia-triggered intracellular delivery of anticancer agent to HER2(+) cells by HER2-specific affibody (ZHER2-GS-Cys)-conjugated thermosensitive liposomes (HER2(+) affisomes). *J Control Release.* 153(2): 187-194, 2011. (ROB)

Zielinski R, Lyakhov I, Hassan M, Kuban M, Shafer-Weaver K, Gandjbakhche A, and **Capala J**: HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors. *Clin Cancer Res.* In press. (ROB)

Dahl M, Bouchelouche P, Kramer-Marek G, **Capala J**, Nordling J, and Bouchelouche K: Sarcosine induces increase in HER2/neu expression in androgen-dependent prostate cancer cells. *Mol Biol Rep.* In press. (ROB)

Molecular Imaging Program - Peter Choyke, M.D.

Daar D, Bernardo M, **Choyke PL**, McKinney Y, and Turkbey B: Prostate Multiparameter MR Imaging. *Radiol Technol.* 82(6): 563MR-568MR, 2011. (MIP)

Kramer-Marek G, Shenoy N, Seidel J, Griffiths GL, **Choyke P**, and Capala J: (68)Ga-DOTA-Affibody molecule for in vivo assessment of HER2/neu expression with PET. *Eur J Nucl Med Mol Imaging.* In press. (MIP)

Shin IS, Lee SM, Kim HS, Yao Z, Regino C, Sato N, Cheng KT, **Hassan R**, Campo MF, Albone EF, **Choyke PL**, **Pastan I**, and Paik CH: Effect of chelator conjugation level and injection dose on tumor and organ uptake of (111)In-labeled MORAb-009, an anti-mesothelin antibody. *Nucl Med Biol.* In press. (MIP)

Nakajima T, Mitsunaga M, Bander NH, Heston WD, **Choyke PL**, and **Kobayashi H**: Targeted, Activatable, In Vivo Fluorescence Imaging of Prostate-specific Membrane Antigen (PSMA)-positive Tumors Using the Quenched Humanized J591 Antibody-ICG Conjugate. *Bioconjug Chem.* In press. (MIP)

Chen L, **Choyke P**, Chan T, Chi C, Wang G, and Wang Y: Tissue-Specific Compartmental Analysis for Dynamic Contrast-enhanced MR Imaging of Complex Tumors. IEEE Trans Med Imaging. In press. (MIP)

Choyke PL: Science to Practice: Pilot Study of FPPRGD2 for Imaging $\alpha_v\beta_3$ Integrin-- How Integral Are Integrins? Radiology. 260(1): 1-2, 2011. (MIP)

Laboratory of Cancer Prevention - Nancy Colburn, Ph.D.

Crea F, Hurt EM, Mathews LA, Cabarcas SM, Sun L, **Marquez VE**, Danesi R, and **Farrar W**: Pharmacologic disruption of polycomb repressive complex 2 inhibits tumorigenicity and tumor progression in prostate cancer. Molecular Cancer. 40: 1-10, 2011. (CBL)

Kasaikina MV, Fomenko DE, Labunskyy VM, Lachke SA, Qui W, Moncaster JA, Zhang J, Wojnarowicz Jr MW, Natarajan SK, Malinouski M, Schweizer U, Tsuji PA, Carlson BA, Maas RL, Lou MF, Goldstein LE, **Hatfield DL**, and Gladyshev VN: 15 kDa selenoprotein (Sep15) knockout mice: roles of Sep15 in redox homeostasis and cataract development. J Biol Chem. In press. (LCP)

Diyabalanage T, Ratnayake R, Wilson JA, Henrich CJ, Beutler JA, **Colburn NH**, **McMahon JB**, and **Gustafson KR**: Nothospondin, a new AP-1 inhibitory quassinoid from the Cameroonian plant Nothospondias staudtii. Bioorg Med Chem Lett. In press. (LCP)

Noubissi FK, Nikiforov MA, **Colburn NH**, and Spiegelman VS: Transcriptional Regulation of CRD-BP by c-myc: Implications for c-myc functions. Genes Cancer. In press. (LCP)

Schmid T, Bajer MM, Blees JS, Eifler LK, Milke L, Rüksamen D, Schulz K, Weigert A, Baker AR, **Colburn NH**, and Brüne B: Inflammation-induced loss of Pcd4 is mediated by phosphorylation-dependent degradation. Carcinogenesis. In press. (LCP)

Cabarcas SM, Mathews LA, and **Farrar WL**: The cancer stem cells niche – there goes the neighborhood? Int J Cancer. In press. (LCP)

Carlson BA, Yoo MH, Shrimali RK, Irons R, Gladyshev VN, **Hatfield DL**, and Park JM: Papel de las selenoproteínas en la función de células T y macrófagos. En Inmunonutrición: En la salud y la enfermedad. (Marcos A. ed). Panamericana. Madrid. PP: 226-239, 2011. (LCP)

Hatfield DL, Berry MJ, and Gladyshev VN (Eds.): Selenium: Its molecular biology and role in human health. 3rd Edition. Springer Science+Business Media, LLC, New York, NY, 2011. pp 598. (Preface and Book Dedication also contributed by the editors). (LCP)

Xu XM, Turanov AA, Carlson BA, Yoo MH, Gladyshev VN, and **Hatfield DL**: Selenocysteine biosynthesis and the replacement of selenocysteine with cysteine in the pathway. In: Selenium: Its molecular biology and role in human health. (**Hatfield DL**, Berry MJ, and Gladyshev VN, Eds.). Chapter 2. 3rd Edition. Springer Science+Business Media, LLC, New York, NY, 2011. (LCP)

Yoo, MH, Carlson BA, Tsuji PA, Tobe R, Naranjo-Suarez S, Lee BJ, Davis CD, Gladyshev VN and **Hatfield DL**: Selenoproteins harboring a split personality in both preventing and promoting cancer. In: Selenium: Its molecular biology and role in human health. (**Hatfield DL**, Berry MJ, and Gladyshev VN, Eds.). Chapter 25. 3rd Edition. Springer Science+Business Media, LLC, New York, NY, 2011. (LCP)

Carlson BA, Yoo MH, Tsuji PA, Tobe R, Naranjo-Suarez S, Chen F, Feigenbaum L, **Tessarollo L**, Lee BJ, Gladyshev VN and **Hatfield DL**: Mouse models that target removal or over-expression of the selenocysteine tRNA gene to elucidate the role of selenoproteins in health and development. In Selenium: Its molecular biology and role in human health. (**Hatfield DL**, Berry MJ, and Gladyshev VN, Eds.). Chapter 44. 3rd Edition. Springer Science+Business Media, LLC, New York, NY, 2011. (LCP)

Kim JY, Carlson BA, Xu XM, Zeng Y, Chen S, Gladyshev VN, Lee BJ, and **Hatfield DL**: Inhibition of selenocysteine tRNA aminoacylation provides evidence that aminoacylation is required for regulatory methylation of this tRNA. *Biochem. Biophys. Res. Commun.* 409: 814-819, 2011. (LCP)

Shchedrina VA, Kabil H, Vorvruggen G, Lee BC, Turanov AA, Hirose-Takamori M, Kim HY, Harshman LG, **Hatfield DL**, and Gladyshev VN: Analyses of fruit flies that do not express selenoproteins or express a mouse selenoprotein, methionine sulfoxide reductase B1, reveal a role of selenoproteins in stress resistance. *J. Biol. Chem.* In press. (LCP)

Shim MS, Kim JY, Lee KH, Jung HK, Carlson BA, Xu XM, **Hatfield DL**, and Lee BJ: I(2)01810 is a novel type of glutamate transporter that is responsible for megamitochondrial formation. *Biochem J.* In press. (LCP)

Neuro-Oncology Branch - Howard Fine, M.D.

There were no submissions reported this month.

Medical Oncology Branch - Giuseppe Giaccone, M.D., Ph.D.

Hollander MC, Zhou X, Maier CR, Patterson AD, Ding X, and **Dennis PA**: A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice. *Carcinogenesis.* In press. (MOB)

Zhang C, Elkahoulou AG, Liao H, Delaney S, Saber B, Morrow B, Prendergast GC, Hollander MC, Gills JJ, and **Dennis PA**: Expression Signatures of the Lipid-Based Akt Inhibitors Phosphatidylinositol Ether Lipid Analogues in NSCLC Cells. *Mol Cancer Ther.* 10(7): 1137-1148, 2011. (MOB)

Marti GE, Stetler-Stevenson M, Grant ND, White T, **Figg WD**, Tohnya T, **Jaffe ES**, Dunleavy K, Janik JE, Steinberg SM, and **Wilson WH**: Phase I trial of 7-hydroxystaurosporine and fludarabine phosphate: in vivo evidence of 7-hydroxystaurosporine induced apoptosis in chronic lymphocytic leukemia. *Leuk Lymphoma*. In press. (MOB)

Voortman J, Schetter AJ, **Harris CC**, and **Giaccone G**: MicroRNA Expression and Outcome in Resected NSCLC--Response. *Cancer Res.* In press. (MOB)

Leon LG, Giovannetti E, Smid K, van Houte BP, Hanauske AR, **Giaccone G**, and Peters GJ: DNA Copy Number Profiles Correlate with Outcome in Colorectal Cancer Patients Treated with Fluoropyrimidine/Antifolate-Based Regimens. *Curr Drug Metab.* In press. (MOB)

Greten TF, Manns MP, and Korangy F: Myeloid derived suppressor cells in human diseases. *Int Immunopharmacol.* 11(7): 802-807, 2011. (MOB)

Mannel RS, Brady MF, **Kohn EC**, Hanjani P, Hiura M, Lee R, Degeest K, Cohn DE, Monk BJ, and Michael H: A randomized phase III trial of IV carboplatin and paclitaxel × 3 courses followed by observation versus weekly maintenance low-dose paclitaxel in patients with early-stage ovarian carcinoma: a Gynecologic Oncology Group Study. *Gynecol Oncol.* 122(1): 89-94, 2011. (MOB)

Buadi F, Hsing AW, Katzmann JA, Pfeiffer RM, Waxman A, Yeboah ED, Biritwum RB, Tettey Y, Adjei A, Chu LW, Demarzo A, Netto GJ, Dispenzieri A, Kyle RA, Rajkumar SV, and **Landgren O**: High prevalence of polyclonal hypergamma-globulinemia in adult males in Ghana, Africa. *Am J Hematol.* 86(7): 554-558, 2011. (MOB)

Laboratory of Metabolism - Frank Gonzalez, Ph.D.

Gilbert-Sirieix M, Makoukji J, **Kimura S**, Talbot M, Caillou B, Massaad C, and Massaad-Massade L: Wnt/beta-catenin signaling pathway is a direct enhancer of thyroid transcription factor-1 in human papillary thyroid carcinoma cells. *PLoS One.* In press. (LM)

Laboratory of Cell Biology - Michael Gottesman, M.D.

Gillet J-P, Wang J, Calcagno AM, Green LJ, Varma S, Bunkholt Elstrand M, Trope CG, **Ambudkar SV**, Davidson B, and **Gottesman MM**: Clinical Relevance of Multidrug Resistance Gene Expression in Ovarian Serous Carcinoma Effusions. *Mol Pharmaceutics.* In press. (LCB)

Hall M, Brimacombe K, Varonka M, Pluchino K, Monda J, Li J, Walsh M, Boxer M, Warren T, Fales H, and **Gottesman MM**: Synthesis and structure-activity evaluation of isatin- β -thiosemicarbazones with improved selective activity towards multidrug-resistant cells expressing P-glycoprotein. J Med Chem. In press. (LCB)

Experimental Transplantation and Immunology Branch - Ronald Gress, M.D.

There were no submissions reported this month.

Laboratory of Receptor Biology and Gene Expression - Gordon Hager, Ph.D.

There were no submissions reported this month.

Laboratory of Human Carcinogenesis - Curtis Harris, M.D.

There were no submissions reported this month.

HIV Drug Resistance Program - Stephen Hughes, Ph.D.

HIV DRP Host Virus Interaction Branch - Stephen Hughes, Ph.D.

There were no submissions reported this month.

Retroviral Replication Laboratory - Stephen Hughes, Ph.D.

There were no submissions reported this month.

Laboratory of Comparative Carcinogenesis - Larry Keefer, Ph.D.

There were no submissions reported this month.

Cell and Cancer Biology Branch - Kathleen Kelly, Ph.D.

There were no submissions reported this month.

Urologic Oncology Branch - W. Marston Linehan, M.D.

There were no submissions reported this month.

Laboratory of Cellular Oncology - Douglas Lowy, M.D.

There were no submissions reported this month.

Pediatric Oncology Branch - Crystall Mackall, M.D.

There were no submissions reported this month.

Genetics Branch - Paul Meltzer, M.D., Ph.D.

There were no submissions reported this month.

Lab of Cancer Biology & Genetics - Glenn Merlino, PhD and Stuart Yuspa, MD

There were no submissions reported this month.

Radiation Biology Branch - James Mitchell, Ph.D.

There were no submissions reported this month.

Laboratory of Cell and Developmental Signaling - Debbie Morrison, Ph.D.

There were no submissions reported this month.

Laboratory of Pathology - J. Carl Oberholtzer, M.D., Ph.D.

Brunt EM, **Kleiner DE**, Behling C, Contos MJ, Cummings OW, Ferrell LD, Torbenson MS, and Yeh M: Misuse of scoring systems. *Hepatology*. 54(1): 369-370, 2011. (LP)

da Silva SP, Resnick E, Lucas M, Lortan J, Patel S, Cunningham-Rundles C, Gatter K, Liu Q, **Jaffe ES**, and Chapel H: Lymphoid proliferations of indeterminate malignant potential arising in adults with common variable immunodeficiency disorders: unusual case studies and immunohistological review in the light of possible causative events. *J. Clin. Immunol.* In press. (LP)

Garcia-Herrera A, Song JY, Chuang SS, Villamor N, Colomo L, Pittaluga S, Alvaro T, Rozman M, de Anda Gonzalez J, Arrunategui AM, Fernandez E, Gonzalvo E, Estrach T, Colomer D, Raffeld M, Gaulard P, Campo E, **Jaffe ES**, and Martinez A: Nonhepatosplenic gammadelta T-cell lymphomas represent a spectrum of aggressive cytotoxic T-cell lymphomas with a mainly extranodal presentation. *Am J Surg Pathol*. 35(8): 1214-1225, 2011. (LP)

Hoefs JC, Shiffman ML, Goodman ZD, **Kleiner DE**, Dienstag JL and Stoddard AM: HALT-C trial group. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C trial. *Gastroenterology*. In press. (LP)

Jegalian AG, Eberle FC, Pack SD, Mirvis M, Raffeld M, Pittaluga S, and **Jaffe ES**: Follicular lymphoma in situ: clinical implications and comparisons with partial involvement by follicular lymphoma. *Blood*. In press. (LP)

Miettinen M and Lasota J: Histopathology of gastrointestinal stromal tumors. *Sem. Surg. Oncol.* In press. (LP)

Miettinen M, Sarlomo-Rikala M, and Wang ZF: Claudin 5 as an immunohistochemical marker for angiosarcoma and hemangioendotheliomas. *Am. J. Surg. Pathol.* In press. (LP)

Miettinen M, Wang ZF, Sarlomo-Rikala M, Osuch C, Rutkowski P, and Lasota J: Succinate dehydrogenase deficient GISTs – a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. *Am. J. Surg. Pathol.* In press. (LP)

Roberts DD: Emerging functions of matricellular proteins. *Cell. Mol. Life Sci.* In press. (LP)

Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, **Kleiner DE**, Deeks SG, Liang TJ, Heller T, and Douek DC: Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. *Gastroenterology.* In press. (LP)

Voltaggio L, Murray R, Lasota J, and **Miettinen M**: Gastric schwannoma – a clinicopathologic study of 51 cases and critical review of the literature. *Hum. Pathol.* In press. (LP)

Laboratory of Genomic Diversity - Stephen O'Brien, Ph.D.

There were no submissions reported this month.

Lab of Molecular Biology - Ira Pastan, M.D. and Susan Gottesman, Ph.D.

Lu C and **Cheng SY**: Extranuclear signaling of mutated thyroid hormone receptors in promoting metastatic spread in thyroid carcinogenesis. *Steroids.* 76: 885-891, 2011. (LMB)

Matsusaka T, Sandgren E, Shintani A, Kon V, **Pastan I**, Fogo AB, and Ichikawa I: Podocyte injury damages other podocytes. *J. Am. Soc. Nephrol.* 22: 1275-1285, 2011. (LMB)

Murata K, Imal M, Nakanishi S, Watanabe D, **Pastan I**, Kobayashi K, Nihira T, Mochizuki H, Yamada S, Mori K, and Yamaguchi M: Compensation of depleted neuronal subsets by new neurons in a local area of adult olfactory bulb. *J. Neurosci.* 31: 10540-10557, 2011. (LMB)

Cancer and Developmental Biology Laboratory - Alan Perantoni, Ph.D.

There were no submissions reported this month.

Laboratory of Molecular Pharmacology - Yves Pommier, M.D., Ph.D.

Kim N, Huang SY, Williams JS, Li YC, Clark AB, Cho JE, Kunkel TA, **Pommier Y**, and Jinks-Robertson S: Mutagenic processing of ribonucleotides in DNA by yeast topoisomerase I. *Science*. 332: 1561-1564, 2011. (LMP)

Luna A, Sunshine M, van Iersel MP, **Aladjem MI**, and **Kohn KW**: Pathvisio-MIM: PathVisio plugin for creating and editing molecular interaction maps (MIMs). *Bioinformatics*. 27: 2165-2166, 2011. (LMP)

Peterson KE, Cinelli MA, Morrell AE, Mehta A, Dexheimer TS, Agama K, Antony S, **Pommier Y**, and Cushman M: Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding and biological activity. *J. Med. Chem.* 54: 4937-4953, 2011. (LMP)

Chiu WT, Lee HT, Huang FJ, Aldape KD, Yao J, **Steeg PS**, Chou CY, Lu Z, Xie K, and Huang S: Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by Stat3 inhibition. *Cancer Res.* 71: 4932-4943, 2011. (LMP)

McGowan PM, Simeanea C, Ribot EJ, Foster PJ, Palmieri D, **Steeg PS**, Allan AL, and Chambers AF: Notch1 inhibition alters the CD44^{hi}/CD24^{lo} population and reduces the formation of brain metastases from breast cancer. *Mol. Cancer Res.* 9: 834-844, 2011. (LMP)

Ribot EJ, Martinez-Santesteban FM, Simeanea C, **Steeg PS**, Chambers AF, Rutt BK, and Foster PJ: In vivo single scan detection of both iron-labeled cells and breast cancer metastases in the mouse brain using balanced steady-state free precession imaging at 1.5 T. *J. Magn. Reson Imaging*. 34: 231-238, 2011. (LMP)

Sooryakumar D, Dexheimer T, Teicher BA, and **Pommier Y**: Molecular and cellular pharmacology of the novel non-camptothecin topoisomerase I inhibitor, Genz-644282. *Mol. Cancer Ther.* In press. (LMP)

Hare S, Smith SJ, Metifiot M, Jaxa-Chamiec A, **Pommier Y**, **Hughes SH**, and Cherepanov P: Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). *Mol. Pharmacol.* In press. (LMP)

Huang L, Fu H, Lin CM, Conner A, Zhang Y, and **Aladjem MI**: Prevention of transcriptional silencing by a replicator-binding complex consisting of SWI/SNF, MeCP1 and hnRNP C1/C2. *Mol. Cell Biol.* In press. (LMP)

Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, **Figg WD**, Chen X, Turkbey IB, **Choyke P**, Murgu AJ, **Doroshov JH**, and Melillo G: Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1 (alpha) in advanced solid tumors. Clin. Cancer Res. In press. (LMP)

Humphrey RW, Brockway-Lunardi LM, Bonk DT, Dohoney KM, **Doroshov JH**, Meech SJ, Ratain MJ, Topalian SL, and Pardoll DM: Opportunities and challenges in the development of experimental drug combinations for cancer. J. Natl. Cancer Inst. In press. (LMP)

Zoppoli G, Solier S, Reinhold WC, Liu H, Connelly Jr JW, Monks A, Shoemaker RH, Abaan OD, Davis SR, **Meltzer PS**, **Doroshov JH**, and **Pommier Y**: CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute. Oncogene. In press. (LMP)

Steeg PS, Zollo M, and Wieland T: A critical evaluation of biochemical activities reported for the nucleoside diphosphate kinase/Nm23/Awd family proteins: opportunities and missteps in understanding their biological functions. Naunyn Schmiedebergs Arch Pharmacol. In press. (LMP)

Percy DB, Ribot EJ, Chen Y, McFadden C, Simeadrea C, **Steeg PS**, Chambers AF, and Foster PJ: In vivo characterization of changing blood-tumor barrier permeability in a mouse model of breast cancer metastasis: a complementary magnetic resonance imaging approach. Invest. Radiol. In press. (LMP)

Marino N, Marshall JC, and **Steeg PS**: Protein-protein interactions: a mechanism regulating the anti-metastatic properties of Nm23-H1. Naunyn Schmiedebergs Arch. Pharmacol. In press. (LMP)

Surgery Branch - Steven Rosenberg, M.D., Ph.D.

Rosenberg SA, **Yang JC**, Sherry RM, **Kammula US**, Hughes MS, Phan GQ, **Citrin DE**, **Restifo NP**, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, and Dudley ME: Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 17(13): 4550-4557, 2011. (SB)

Mammary Biology & Tumorigenesis Lab – David Salomon, Ph.D. (Acting Lab Chief)

Klauzinska M, Baljinnyam B, Raafat A, Rodriguez-Canales J, Strizzi L, Endo-Greer Y, **Rubin JS**, and **Callahan R**: *Rspo2/Int7* and *Wnt1* regulate invasiveness and tumorigenic properties of mammary epithelial cells. J. Cell. Phys. In press. (MBTL)

Chiluiza D, Bargo S, **Callahan R**, and Rhoads RE: Expression of truncated eIF3e resulting from integration of MMTV causes a shift from cap-dependent to cap-independent translation. J. Biol. Chem. In press. (MBTL)

Laboratory of Cellular and Molecular Biology - Larry Samelson, M.D.

There were no submissions reported this month.

Laboratory of Tumor Immunology and Biology - Jeffrey Schlom, Ph.D.

Whiteside TL, **Gulley JL**, Clay TM, and **Tsang KY**: Immunologic monitoring of cellular immune responses in cancer vaccine therapy (editorial). J Biomed Biotechnol. In press. (LTIB)

Tsang KY and **Gulley JL**: Highlights on FOXO3 and tumor-associated dendritic cells in prostate cancer. Asian J Androl. In press. (LTIB)

Gulley JL, **Madan RA**, and **Schlom J**: Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol. 18(3): e150-157, 2011. (LTIB)

Gulley J: New frontiers in therapy for metastatic prostate cancer (editorial). Drug Discov Today: Ther Strategies. In press. (LTIB)

Experimental Immunology Branch - Alfred Singer, M.D.

There were no submissions reported this month.

Gene Regulation and Chromosome Biology Lab - Jeffrey Strathern, Ph.D.

There were no submissions reported this month.

Laboratory of Experimental Carcinogenesis - Snorri Thorgeirsson, M.D., Ph.D.

Coulouarn C, Factor VM, Conner EA, and **Thorgeirsson SS**: Genomic modeling of tumor onset and progression in a mouse model of aggressive human liver cancer. Carcinogenesis. In press. (LEC)

Cancer and Inflammation Program - Giorgio Trinchieri, M.D.

Laboratory of Molecular Immunoregulation - Joost Oppenheim, M.D.

There were no submissions reported this month.

Laboratory of Experimental Immunology - Giorgio Trinchieri, M.D.

Reizis B, Colonna M, **Trinchieri G**, Barrat F, and Gilliet M: Plasmacytoid dendritic cells: one-trick ponies or workhorses of the immune system? *Nat Rev Immunol.* 11: 558-565, 2011. (LEI)

Li JZ, Brumme CJ, Lederman MM, Brumme ZL, Wang H, Spritzler J, Robertson MN, **Carrington M**, Walker BD, Schooley RT, Kuritzkes DR, and The AIDS Clinical Trial Group A5197 Study Team: Characteristics and outcomes of initial virologic suppressors following therapeutic HIV-1 gag vaccination. *PLoS One.* In press. (LEI)

Wang Y, Oniangue-Ndjal C, Qi Y, Wang A, Scheidewindl A, Kemper M, Mellors E, Gladden AD, Power KA, Pierce BG, McLaren P, de Bakker PIW, Rauch A, Telenti A, Deeks SG, Haas DW, Gao X, Pereyra F, Walker BD, **Carrington M**, and Allen TM: Cooperative effects of combinations of HLA class I alleles on the control of HIV. *PLoS Pathogens.* In press. (LEI)

Novikov A, Cardone M, Thompson R, Shenderov K, Kirschman KD, Mayer-Barber KD, Myers TG, Rabin RL, **Trinchieri G**, Sher A, and Feng CG: Mycobacterium tuberculosis Triggers Host Type I IFN Signaling To Regulate IL-1 β Production in Human Macrophages. *J. Immunol.* In press. (LEI)

Dermatology Branch - Mark Udey, M.D., Ph.D.

There were no submissions reported this month.

Mouse Cancer Genetics Program - Terry Van Dyke, Ph.D.

There were no submissions reported this month.

Metabolism Branch - Thomas Waldmann, M.D.

There were no submissions reported this month.

Laboratory of Protein Dynamics & Signaling - Allan Weissman, M.D.

Lipkowitz S and **Weissman AM**: RINGs of Good and Evil: RING finger ubiquitin-protein ligases at the crossroads of tumor suppression and oncogenesis. *Nat. Rev. Cancer.* In press. (LPDS)

Weissman AM, Shabek N, and Ciechanover A: The predator becomes the prey: regulating the ubiquitin system by ubiquitylation and degradation. *Nat. Rev. Mol. Cell. Bio.* In press. (LPDS)

Tsai YC and **Weissman AM**: Dissecting the diverse functions of the metastasis suppressor CD82/KAI1. *FEBS Lett.* In press. (LPDS)

Macromolecular Crystallography Laboratory - Alexander Wlodawer, Ph.D.

There were no submissions reported this month.

Laboratory of Biochemistry and Molecular Biology - Carl Wu, Ph.D.

There were no submissions reported this month.

HIV and AIDS Malignancy Branch - Robert Yarchoan, M.D.

There were no submissions reported this month.

Basic Research Laboratory

There were no submissions reported this month.

Emeritus Scientists

There were no submissions reported this month.